EMA advises continued use of medicines for hypertension, heart or kidney disease during COVID-19 pandemic

The EMA have stated that the speculation that ACE-inhibitors or ARBs treatment can make infections worse in the context of COVID-19 is not currently supported by clinical evidence, and they state that there is currently no reason for patients to stop these treatments.


European Medicines Agency